ArticleEuropean journal of nuclear medicine and molecular imaging2024
Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 17 citations in OpenAlex.
- Advances in PD-L1 Targeted Molecular Imaging Radiotracers Research: From Preclinical Exploration to Clinical Application.Molecular imaging and biology · 2026Review
- Synthesis and Preclinical Evaluation of Dual-Targeted Molecular Tracer for Positron Emission Tomography Imaging of Programmed Cell Death Ligand‑1 and Integrin αACS pharmacology & translational science · 2025Article
- Relationship between PD-L1 expression and [European journal of nuclear medicine and molecular imaging · 2025Article
- Preclinical evaluation and preliminary clinical study ofCancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- A PD-L1-Targeted Probe Cy5.5-A11 forACS omega · 2024Article
- Challenges coexist with opportunities: development of a macrocyclic peptide PET radioligand for PD-L1.European journal of nuclear medicine and molecular imaging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
purposeDue to tumor heterogeneity, immunohistochemistry (IHC) showed poor accuracy in detecting the expression of programmed cell death ligand-1 (PD-L1) in patients. Positron emission tomography (PET) imaging is considered as a non-invasive technique to detect PD-L1 expression at the molecular level visually, real-timely and quantitatively. This study aimed to develop novel peptide-based radiotracers [
methodsNOTA-IMB was prepared by connecting 2,2'-(7-(2-((2,5-dioxopyrrolidin-1-yl)oxy)- 2-oxoethyl)-1,4,7-triazonane-1,4-diyl) diacetic acid (NOTA-NHS) with PD-L1-targeted peptide IMB, and further radiolabeled with
results[
conclusion[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.